Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.

Bibliographic Details
Main Authors:	Curtis Cooper, Stephen Shafran, Susan Greenbloom, Robert Enns, John Farley, Nir Hilzenrat, Kurt Williams, Magdy Elkashab, Nabil Abadir, Manuela Neuman
Format:	Article
Language:	English
Published:	Hindawi Limited 2014-01-01
Series:	Canadian Journal of Gastroenterology and Hepatology
Online Access:	http://dx.doi.org/10.1155/2014/367131

Similar Items

Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C
by: Yvette Leung, et al.
Published: (2006-01-01)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
by: Yasser K. Rashed, et al.
Published: (2020-02-01)

Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
by: Konstantinos D. Pantazis, et al.
Published: (2008-01-01)

The Study on Adverse Events Induced byPegylated Interferon Alpha plus Ribavirin in Chronic Hepatitis C
by: Shu-Hui Kuo, et al.
Published: (2007)

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4
by: Juan José Urquijo, et al.
Published: (2013-01-01)

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)

Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy.
by: Mark A A Claassen, et al.
Published: (2012-01-01)

Three Patients with Viral Breakthrough during Pegylated Interferon Alpha-2b and Ribavirin Therapy: A Case Series
by: Daigo Kon, et al.
Published: (2011-01-01)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
by: Nishikawa Hiroki, et al.
Published: (2012-03-01)

The Influenced factors of the Efficacy and Anemia Adverse Effects Induced by Pegylated Interferon Alpha plus Ribavirin in Chronic Hepatitis C
by: Chun-Nan, et al.
Published: (2012)

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01)

INFLIXIMAB AND TUMOUR NECROSIS FACTOR ALPHA MEASUREMENT ON INTESTINAL MUCOSA: A NEW TOOL FOR THE CLINIC?
by: Silvia Pecere, et al.
Published: (2016-12-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.
by: Tetsuro Takayama, et al.
Published: (2011-01-01)

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn’s Disease
by: Ashley Fonseca, et al.
Published: (2021-01-01)

Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin
by: McGarrity Thomas J, et al.
Published: (2006-05-01)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
by: Maryam Keshvari, et al.
Published: (2016-01-01)

Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
by: Malgorzata Inglot, et al.
Published: (2013-03-01)

Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
by: Giulia Marchetti, et al.
Published: (2012-01-01)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
by: Younossi Zobair M, et al.
Published: (2012-02-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation
by: J Shepherd, et al.
Published: (2004-10-01)

Pegylated-Interferon Alpha 2b and Ribavirin for Recurrent Hepatitis C after Liver Transplantation: From a Canadian Experience to Recommendations for Therapy
by: Mohamed Babatin, et al.
Published: (2005-01-01)

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
by: Antonio Rivero-Juárez, et al.
Published: (2012-01-01)

Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality
by: LIN Wei, et al.
Published: (2015-11-01)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
by: Kamil Grubczak, et al.
Published: (2021-07-01)

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
by: Jaber Al-Ali, et al.
Published: (2012-03-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN α) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1.
by: Krasimir Antonov, et al.
Published: (2011-12-01)

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial
by: Miguel Ángel Jiménez-Luévano, et al.
Published: (2013-03-01)

Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians
by: Curtis L Cooper, et al.
Published: (2008-01-01)

Evaluation of the Results of Patients Treated By Pegylated Interferon Alpha Therapy
by: Çiğdem PAPİLA, et al.
Published: (2015-09-01)

Response of Hepatitis C Patients to Alpha Interferon and Ribavirin Combination Therapy
by: Ihsanullah Mahsud, et al.
Published: (2004-06-01)

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease
by: J Dretzke, et al.
Published: (2011-02-01)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
by: Yan-Ming Zeng, et al.
Published: (2020-05-01)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
by: Amit Chopra, et al.
Published: (2015-01-01)

Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
by: Benjamin Heidrich, et al.
Published: (2014-01-01)

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment
by: Kainuma Mosaburo, et al.
Published: (2010-04-01)

Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis
by: Motoi Uchino, et al.
Published: (2017-10-01)